of TCM modernization. In a network pharmacology study, drug-drug networks can be constructed based on the similarities in the structures and efficacies of different drugs. In the process of TCM modernization, some researchers have achieved good initial results in exploring the essential properties of TCMs and revealing their comprehensive overall effects on multi-pathways, multi-targets and multi-components via the research ideas of network pharmacology.
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Xanthii Fructus (XF) is the ripe fruit of Xanthium sibiricum Patr. XF is used for the treatment of cramping, numbness of the limbs, ulcers, sinusitis, catarrhs, and pruritus, for its function in smoothing nasal orices and eliminating wind-dampness.
12
In modern clinic application, XF is commonly used for the treatment of rhinitis. Particularly when combined with Magnoliae os, mint and other Chinese medicines, XF has enhanced effects in curing chronic rhinitis, allergic rhinitis and other rhinitis. 13 
Materials and methods

Screening active ingredients
In our previous study (unpublished), components such as myristic acid, succinic acid, xanthosine, emodin, apigenin, and chrysophanol were identied from serum samples aer oral administration of XF extracts. Components such as cleomiscosin A and sitostenone were ltered using the traditional Chinese medicine systems pharmacology (TcmSP™) database, and the parameters were set as follows: oral bioavailability (OB) $ 30%, drug-likeness (DL) $ 0.18. The structures of the components mentioned above are shown in Fig. 1 .
Prediction of active component targets
Firstly, the MDL SD (*.sdf) type les of the above active ingredients were searched using the PubMed database. Secondly, targets, including information like the target name, matching value, target protein abbreviation, function, disease and applicable results related to the modied compound, could be predicted by importing each component le in *sdf format into the PharmMapper database. The top 20 high-matching targets, by value, were used as the TCM target proteins related to the components. The targets were then searched for in the UniProt database to identify human-related target codes.
Pathway comments and analysis
The retrieved target protein information was analyzed using the Reactome database to obtain the result of the related pathway Fig. 1 Structures of the components.
"pathwayIdexByPathway_kegg". A pathway was selected as reliable when its P value was less than 0.01.
Drug-target-pathway relationship
The predicted targets of ve chemical components of XF, namely cleomiscosin A, myristic acid, succinic acid, xanthosine and sitostenone, were recorded in excel tables titled as 'component-protein' and 'protein-pathway'. The tables were imported into Cytoscape soware to construct the main effect components of the XF-target-pathway network. The network was mainly composed of three types of nodes: effect component, protein and pathway. The effect components and their related target proteins, and the proteins and their related pathways were all side-linked. When the target protein of the effect component was the same as the target protein of the pathway, the effect component was side-linked to the pathway. A complete network diagram was built by the establishment of connections including effect component-protein-pathway, effect component-protein-effect component, pathway-proteinpathway, protein-effect component-protein and other four kinds of connection. The whole framework, based on the active component strategy of system pharmacology, is shown in Fig. 2. 
Results
Potential target information for ve components in XF
Eight components in XF were initially selected to uncover potential target proteins. Of these, ve components, namely cleomiscosin A, myristic acid, succinic acid, xanthosine, and sitostenone, were successfully analyzed. A total of 99 target proteins were related to these ve XF components as shown in Table 1 . The frequency of some target proteins was much higher than that of others; high frequencies were obtained for P15086, P07360, P07195, MAOM_HUMAN (P23368), P35558, P35520, ACE_HUMAN (P12821), C1S_HUMAN (P09871), PH4H_HUMAN (P00439), FPPS_HUMAN (P14324), P50613, P12724, IMPA1_-HUMAN (P29218), HXK1_HUMAN (P19367), P14061, and MCR_HUMAN (P08235).
Pathway analysis of potential target proteins
The potential pathway information for the ve effect components in XF is shown in Table 2 .
Main effect component-target protein-pathway network construction for XF
An effect component-target-pathway network model was established using Cytoscape soware, and the relationship between the 5 components, 99 targets and 52 pathways is shown in Fig. 3 . There were complex network relationships between the effect components of XF and their targets, as well as the targets and pathways.
Cleomiscosin A was related to the following pathways: nuclear receptor transcription pathway (Pw1), activation of the AP-1 family of transcription factors (Pw2), MAPK targets/nuclear events mediated by MAP kinases (Pw3), p38MAPK events (Pw4), Generic Transcription Pathway (Pw5), Transcriptional regulation by RUNX2 (Pw6), Signalling to RAS (Pw7), RNA Polymerase II Transcription (Pw8), Regulation of TP53 Activity through Phosphorylation (Pw9), Metabolism (Pw10), Nuclear Events (kinase and transcription factor activation) (Pw11), MAP kinase Fig. 2 The whole framework of system pharmacology. A  P06276  CHLE_HUMAN  3  2  Cleomiscosin A  P23141  EST1_HUMAN  3  3  Cleomiscosin A  P62937  P62937  3  4  Cleomiscosin A  P00918  CAH2_HUMAN  3  5  Cleomiscosin A  P24941  P24941  3  6  Cleomiscosin A  P07339  CATD_HUMAN  3  7  Cleomiscosin A  P03372  ESR1_HUMAN  3  8  Cleomiscosin A  Q15078  CD5R1_HUMAN  3  9  Cleomiscosin A  P00915  CAH1_HUMAN  3  10  Cleomiscosin A  P04062  GLCM_HUMAN  3  11  Cleomiscosin A  P11309  PIM1_HUMAN  3  12 Cleomiscosin P12724  P12724  6  60  Xanthosine  Q9BW91  Q9BW91  3  61  Xanthosine  P37173  TGFR2_HUMAN  3  62  Xanthosine  P04062  GLCM_HUMAN  3  63  Xanthosine  O14965  STK6_HUMAN  3  64 Xanthosine Q13126 Q13126 3 65  Xanthosine  P00533  EGFR_HUMAN  3  66  Xanthosine  P24941  P24941  4  67  Xanthosine  Q07343  PDE4B_HUMAN  3  68  Xanthosine  P00915  CAH1_HUMAN  3  69  Xanthosine  Q12884  SEPR_HUMAN  3  70  Xanthosine  O14757  CHK1_HUMAN  3  71  Xanthosine  Q05315  LPPL_HUMAN  3  72  Xanthosine  P04745  P04745  3  73  Xanthosine  P18075  BMP7_HUMAN  4  74  Xanthosine  P03950  ANGI_HUMAN  4  75  Xanthosine  P00491  PNPH_HUMAN  4  76  Xanthosine  P29218  IMPA1_HUMAN  5  77  Xanthosine  Q99933  BAG1_HUMAN  4  78  Xanthosine  P19367  HXK1_HUMAN  5  79  Xanthosine  P17707  DCAM_HUMAN  4  80  Sitostenone  P52895  AK1C2_HUMAN  3  81  Sitostenone  P49137  P49137  3  82  Sitostenone  P55210  CASP7_HUMAN  3  83  Sitostenone  P12643  BMP2_HUMAN  3  84  Sitostenone  P08842  STS_HUMAN  3  85  Sitostenone  P27338  AOFB_HUMAN  3  86  Sitostenone  P02774  VTDB_HUMAN  4  87  Sitostenone  P11309  P11309  3  88  Sitostenone  P02768  ALBU_HUMAN  3  89  Sitostenone  P28482  MK01_HUMAN  3  90  Sitostenone  P45452  MMP13_HUMAN  4  91  Sitostenone  P10828  P10828  3  92  Sitostenone  P52732  KIF11_HUMAN  3  93  Sitostenone  P00918  CAH2_HUMAN  3  94  Sitostenone  P14061  P14061  5  95  Sitostenone  P02652  APOA2_HUMAN  3  96  Sitostenone  P08235  MCR_HUMAN  5  97  Sitostenone  P06401  PRGR_HUMAN  4  98  Sitostenone  P10275  ANDR_HUMAN  3  99  Sitostenone  P02766  TTHY_HUMAN  3 mediated TLR4 signaling (Pw44), MyD88-independent TLR4 cascade (Pw45), Regulation of TP53 Activity (Pw48), Signaling by Receptor Tyrosine Kinases (Pw49), Cellular Senescence (Pw50) and Interleukin-12 family signaling (Pw52). Myristic acid was related to the following pathways: nuclear receptor transcription pathway (Pw1), Activation of the AP-1 family of transcription factors (Pw2), MAPK targets/nuclear events mediated by MAP kinases (Pw3), p38MAPK events (Pw4), Generic Transcription Pathway (Pw5), Transcriptional regulation by RUNX2 (Pw6), Signalling to RAS (Pw7), RNA Polymerase II Transcription (Pw8), Metabolism (Pw10), Nuclear Events (kinase and transcription factor activation) (Pw11), RUNX2 regulates osteoblast differentiation (Pw12), Metabolism of steroids (Pw13), MAP kinase activation in TLR cascade (Pw14), RUNX2 regulates bone development (Pw16), Signalling to ERKs (Pw17), Gene expression (Transcription) (Pw18), Interleukin-12 family signaling 3
Discussion
The PharmMapper database can be used to search for potential targets based on small active molecules. This database uses a pharmacophore matching method to obtain drug point information by rapidly searching four major databases. This database is based on 7000 pharmacophore models and can cover most clinical indications. According to the network pharmacological prediction of the ve components in XF, all ve components can be connected with the same pathway via the same target, and also can be connected with the same pathways with different targets. Different components can produce the same effect through different ways, and also can offer multi-target synergy.
Interestingly, this predicted common pathway is consistent with the result we got from the metabolic pathway analysis experiment (unpublished), which indicates that this result is reliable although it still requires further verication.
Conclusion
In this paper, a network pharmacology method has been successfully developed to predict the potential targets of the main components absorbed in serum aer oral administration of XF extract. When considered alongside our previous antiallergic rhinitis metabolomics study, the predicted potential targets and the role of the pathways were considered to have a certain degree of accuracy. This article has established a "multi component-multi target-multi pathway" network model for TCM research, and started to unravel the multidimensional regulatory action of XF, which may provide a reference and basis for studying the molecular mechanism of XF.
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